Introduction Few studies have examined outcomes and potential complications among
glaucoma patients who are prescribed topical beta-blockers. This study examined resource …

Purpose: Prescribing topical beta‐blockers for patients with glaucoma, who are also being
treated with systemic beta‐blockers, raises efficacy and safety concerns. This potentially …

Purpose: β-adrenergic receptor antagonists (β-blockers) used in the treatment of glaucoma
are an often-overlooked source of systemic adverse events. Ophthalmic timolol has been …

Objective To determine if topical beta-blocker use is associated with increased risks of
cardiovascular and respiratory diseases in patients with glaucoma. Setting A retrospective …

Br J Ophthalmol: first published as 10.1136/bjo. 86.6. 691 on 1 June 2002. Downloaded
from more potent than dipivefrin and less likely to provoke surface discomfort or allergic …

[Development of additive systemic effects when taking β-blockers in patients with glaucoma
and concurrent chronic diseases]. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

This set of Viewpoints articles examines the merits of beta-blockers versus other
medications as the primary drug treatment for glaucoma. Ophthalmologists must balance …

• Patients being considered for anti-glaucoma therapy with a β-blocking agent should be
assessed for any potential cardiovascular or respiratory risk by a medical practitioner (eg …

The introduction of topical timolol maleate in 1978 revolutionized the medical treatment of
glaucoma. 26 Timolol, as with all the topical beta-receptor antagonists, reduces intraocular …

Objectives: Topical β-blockers are contraindicated in obstructive pulmonary diseases
(OPDs). In this study we aimed to evaluate through central or local electronic medical …